EyePoint Pharmaceuticals, Inc.
EYPTEyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
Drugs in Pipeline
7
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Aug 5, 2026
TomorrowMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
EYPT Earnings Report
EPS Est: $-0.92 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How EYPT's past catalysts played out
Aflibercept (2.0 mg)
Wet Age Related Macular Degeneration
FAI insert
Non-Infectious Uveitis
FAI Insert administered using the Mk II inserter
Non-Infectious Uveitis
EYP-1901
Diabetic Macular Edema
AKB-9778
Nonproliferative Diabetic Retinopathy
Aflibercept 2mg/0.05mL Inj,Oph
Wet Age-related Macular Degeneration
Latanoprost ophthalmic solution
Ocular Hypertension
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Aflibercept (2.0 mg) | Phase 3 | Wet Age Related Macular Degeneration | - | - |
FAI insert | Phase 3 | Non-Infectious Uveitis | - | - |
FAI Insert administered using the Mk II inserter | Phase 3 | Non-Infectious Uveitis | - | - |
EYP-1901 | Phase 3 | Diabetic Macular Edema | - | - |
AKB-9778 | Phase 2 | Nonproliferative Diabetic Retinopathy | - | - |
Aflibercept 2mg/0.05mL Inj,Oph | Phase 2 | Wet Age-related Macular Degeneration | - | - |
Latanoprost ophthalmic solution | Phase 2 | Ocular Hypertension | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in EyePoint Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in EyePoint Pharmaceuticals, Inc.'s (EYPT) pipeline across Phase 3, Phase 2. Its lead program is Aflibercept (2.0 mg) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is EyePoint Pharmaceuticals, Inc.'s next FDA catalyst?→
EyePoint Pharmaceuticals, Inc.'s (EYPT) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EYPT biotech catalysts?→
Add EYPT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow EyePoint Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.